Loading...
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
Howell, Sacha J Krebs, Matthew G Lord, S. Kenny, L. Bahl, A. Clack, G. Ainscow, E. Arkenau, H. T. Mansi, J. L. Palmieri, C.
Howell, Sacha J
Krebs, Matthew G
Lord, S.
Kenny, L.
Bahl, A.
Clack, G.
Ainscow, E.
Arkenau, H. T.
Mansi, J. L.
Palmieri, C.
Citations
Altmetric:
Abstract
Background
CDK7 inhibition is a promising therapeutic strategy in cancer; acting as a regulator of transcription, the cell cycle and endocrine receptor signalling. Patients with HR+BC post CDK4/6 inhibitor treatment have a poor prognosis; median progression free survival (mPFS) of ? 8 weeks for fulvestrant post CDK4/6i in HR+BC [1,2]. Pre-clinical HR+BC models indicate the potential for synergy when the CDK7 inhibitor samuraciclib is combined with fulvestrant [3].
Methods
This single arm cohort assessed the tolerability and efficacy of samuraciclib in combination with fulvestrant in patients with advanced HR+BC; all patients had previously received an aromatase inhibitor and a CDK4/6 inhibitor for advanced disease.
Results
31 patients with HR+BC received the combination of standard dose with fulvestrant and samuraciclib. 6 patients received samuraciclib dose of 240mg once daily (OD) and 25 patients a dose of 360mg (OD). The combination treatment was generally well tolerated, with adverse drug reactions (AE) of note being G1-2 nausea, vomiting and diarrhoea; the majority of patients staying on treatment until disease progression. RECIST evaluation indicates evidence of reduction in tumor disease burden, including a partial response in one patient who has been on treatment for ? 1 year. Graphic illustrations of data, including �waterfall� and �swimmer� plots, will be presented.
Conclusions
Samuraciclib has demonstrated an acceptable safety profile with evidence of anti-tumour activity in combination with fulvestrant for patients with advanced HR+BC who have progressed on their prior CDK4/6i.
Description
Date
2021
Publisher
Collections
Files
Loading...
From Unpaywall
Adobe PDF, 127.26 KB
Keywords
Type
Other
Citation
Howell SJ, Krebs MG, Lord S, Kenny L, Bahl A, Clack G, et al. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S477�8.